Eric Lander talks CRISPR and the infamous Nobel ‘rule of three’
By Joel Achenbach,
The Washington Post
| 04. 21. 2016
Untitled Document
“Funny tensions in science.” That’s a phrase from the lips of Eric Lander, president and founding director of the Broad Institute of MIT and Harvard.
He was in Washington earlier this week to appear at the Aspen Institute in conversation with journalist/biographer Walter Isaacson, and inevitably the talk turned to CRISPR, the revolutionary gene-editing technique, and to Lander’s controversial essay earlier this year in the journal Cell, “The Heroes of CRISPR.” The scientific community's reaction highlighted the aforementioned funny tensions; as my colleague Carolyn Johnson reported, Lander's review of the history of CRISPR set off an epic social-media kerfuffle.
In the essay, Lander distributed credit widely for the CRISPR discovery – which rankled some parties who thought they deserved more attention, or felt that Lander had overemphasized the contribution of one of his Broad Institute colleagues. He described CRISPR as the result of many converging innovations, rather than as something that erupted in a classic Eureka! moment. (In this sense, CRISPR is like the computer; as my friend Walter's book "The Innovators" points out, no single person...
Related Articles
By Keith Casebonne and Jodi Beckstine [with CGS' Katie Hasson], Disability Deep Dive | 07.24.2025
In this episode of Disability Deep Dive, hosts Keith and Jodi explore the complex interplay between disability science, technology, and ethics with guest Katie Hasson, Associate Director at the Center for Genetics and Society. The conversation delves into...
By Angus Liu, Fierce Pharma | 07.22.2025
A brief skirmish between Sarepta Therapeutics and the FDA has ended before escalating into a full-on regulatory clash, as the company has bowed to the agency’s demand.
In a surprising reversal, Sarepta on Monday said it will pause all shipments...
By Lucy Tu, The Atlantic | 07.11.2025
Donald Trump—who is, by his own accounting, “the fertilization president” and “the father of IVF”—wants to help Americans reproduce. During his 2024 campaign, he promised that the government or insurance companies would cover the cost of in vitro fertilization. In...
By Jared Whitlock, Endpoints News | 07.15.2025
Patient groups face a harder and unpredictable path going state-by-state to boost screening for rare but treatable conditions after the Trump administration disbanded a federal advisory committee on newborn screening.
In April, the Advisory Committee on Heritable Disorders in Newborns...